Medical News

RSS

Research: Mediterranean diet linked to lower risk of diabetes

Adoption of a Mediterranean diet is linked to a lower risk of diabetes, especially among people at high risk for cardiovascular disease, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.

27 Mar 2014

New drug multiplies analgesic effect of opioids without increasing constipation

Scientists from the University of Granada have taken part, alongside the Esteve laboratory, in the development of a new drug that multiplies the analgesic effect of opioids (drugs for treating intense pain), without increasing constipation, one of the most common side-effects of these drugs, among which is morphine.

27 Mar 2014

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders:

27 Mar 2014

Jury returns verdict in favor of Mylan in breach of contract case against GSK

Mylan Inc. today announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride Extended-release (ER) Tablets.

27 Mar 2014

Study to understand how protein motor works for development of targeted cancer therapies

Researchers at Warwick Medical School have shown for the first time how a protein motor, Kif15, uses acrobatic flexibility to navigate within the mitotic spindle. Understanding how it works could prove vital for the development of targeted cancer therapies.

27 Mar 2014

National MS Society invests $29M to support new MS research projects, training awards

The National Multiple Sclerosis Society has committed another $29 million to support an expected 83 new MS research projects and training awards.

27 Mar 2014

Treatment option for women with squamous cell carcinoma of the vulva

A team of researchers from Women & Infants Hospital of Rhode Island commanded a national stage to present the results of a study evaluating the use of sentinel lymph node dissection in women with vulvar malignancies, and then follow the patients for complications and recurrence.

27 Mar 2014

Senhwa Biosciences to present CX-5461 study results at AACR meeting

Senhwa Biosciences, Inc. announced today that results from research with its first-in-class Pol I inhibitor, CX-5461, will be presented at the 2014 American Association for Cancer Research (AACR) annual meeting held on April 5-9 in San Diego, CA.

27 Mar 2014

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets.

From Baxter International Inc. 27 Mar 2014

Spherix closes private placement of common stock, terminates private offering

Spherix Incorporated (the "Company") today announced that it has closed a private placement of common stock and warrants and terminated the private offering.

27 Mar 2014

CT scans allow rheumatologists to diagnose gout

Gout is on the rise among U.S. men and women, and this piercingly painful and most common form of inflammatory arthritis is turning out to be more complicated than had been thought.

27 Mar 2014

Cardiome Pharma announces Q4 and full year 2013 results

Cardiome Pharma Corp. today reported financial results for the fourth quarter and year ended December 31, 2013.

27 Mar 2014

Economic growth has little to no effect on nutritional status of world's poorest children

A large study of child growth patterns in 36 developing countries finds that, contrary to widely held beliefs, economic growth has little to no effect on the nutritional status of the world's poorest children.

27 Mar 2014

PrescribeWellness and APhA Foundation join forces to provide community pharmacies

At the American Pharmacists Association (APhA) Convention here today, PrescribeWellness announced a partnership with the APhA Foundation to provide community pharmacies new tools to help their diabetic patients improve their disease management and health.

27 Mar 2014

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).

27 Mar 2014

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

BioDelivery Sciences International, Inc. announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence.

27 Mar 2014

Researchers develop fluorescent sensor to identify presence of drug in less than 30 seconds

A team of researchers from the National University of Singapore (NUS) has developed the world's first fluorescent sensor to identify the presence of a drug known as GHB that is commonly used to spike beverages.

27 Mar 2014

Polymer Technology Systems changes its name to Chek Diagnostics

Polymer Technology Systems, Inc. (PTS, Inc.), the U.S.-based manufacturer of point-of-care diagnostic products, announced today that it is changing its name to Chek Diagnostics.

27 Mar 2014

Researchers discover new way of giving people sweet dreams

Today psychologist Professor Richard Wiseman from the University of Hertfordshire announces the results of a two-year study into dream control. The experiment shows that it is now possible for people to create their perfect dream, and so wake up feeling especially happy and refreshed.

27 Mar 2014

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014